Non-coding Sequences Having No Known Regulatory Function Which Are Adaptors Or Linkers For Vector Or Gene Contruction Patents (Class 536/24.2)
  • Patent number: 8062885
    Abstract: The present invention provides for the nucleic acid sequences of plant centromeres. This will permit construction of stably inherited recombinant DNA constructs and minichromosomes which can serve as vectors for the construction of transgenic plant and animal cells.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 22, 2011
    Assignees: The University of Chicago, Chromatin, Inc.
    Inventors: Jennifer M. Mach, Helge Zieler, RongGuan Jin, Kevin Keith, Gregory P. Copenhaver, Daphne Preuss
  • Patent number: 8063023
    Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: November 22, 2011
    Assignee: Coda Therapeuctics, Inc.
    Inventors: David L. Becker, Colin R. Green, Bradford J. Duft
  • Patent number: 8058061
    Abstract: Recombinant lentiviral vectors having a region encoding a functional ?-globin gene; and large portions of the ?-globin locus control regions which include DNase I hypersensitive sites HS2, HS3 and HS4 provides expression of ?-globin when introduced into a mammal, for example a human, in vivo. Optionally, the vector further includes a region encoding a dihydrofolate reductase. The vector may be used in treatment of hemoglobinopathies, including ?-thalessemia and sickle-cell disease. For example, hematopoietic progenitor or stem cells may be transformed ex vivo and then restored to the patient. Selection processes may be used to increase the percentage of transformed cells in the returned population. For example, a selection marker which makes transformed cells more drug resistant than untransformed cells allows selection by treatment of the cells with the corresponding drug.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: November 15, 2011
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Michel Sadelain, Stefano Rivella, Chad May, Joseph Bertino
  • Patent number: 8034914
    Abstract: A nucleic acid construct that includes (i) a first nucleic acid sequence encoding TNF alpha; (ii) a second nucleic acid sequence encoding a Diphtheria toxin; and (iii) at least one additional nucleic acid sequence of a cancer specific promoter. The TNF alpha and Diphtheria toxin encoding sequences are under an expression control of the cancer specific promoter. Also provided are construct systems and methods and uses of same.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: October 11, 2011
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventor: Avraham Hochberg
  • Patent number: 8030460
    Abstract: A compound having the general formula shown below: where R1-6 are independently selected from the group consisting of an electron withdrawing group, an alkyl group, an aryl group, hydrogen, a heteroaryl group, and a five or six member ring structure formed from the R1 and R2 pair, the R3 and R4 pair, the R4 and R5 pair, or the R5 and R6 pair; R7 is a substituted or unsubstituted aryl group; and Y is a nucleophile.
    Type: Grant
    Filed: August 10, 2010
    Date of Patent: October 4, 2011
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Andrei Laikhter, Joseph A. Walder, Mark Behlke, Mikhail Podyminogin, Yawfui Yong
  • Patent number: 8013136
    Abstract: One aspect of the present invention relates to a ribonucleoside substituted with a phosphonamidite group at the 3?-position. In certain embodiments, the phosphonamidite is an alkyl phosphonamidite. Another aspect of the present invention relates to a double-stranded oligonucleotide comprising at least one non-phosphate linkage. Representative non-phosphate linkages include phosphonate, hydroxylamine, hydroxylhydrazinyl, amide, and carbamate linkages. In certain embodiments, the non-phosphate linkage is a phosphonate linkage. In certain embodiments, a non-phosphate linkage occurs in only one strand. In certain embodiments, a non-phosphate linkage occurs in both strands. In certain embodiments, a ligand is bound to one of the oligonucleotide strands comprising the double-stranded oligonucleotide. In certain embodiments, a ligand is bound to both of the oligonucleotide strands comprising the double-stranded oligonucleotide.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: September 6, 2011
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Patent number: 7993913
    Abstract: The invention provides engineered plant minichromosomes generated by telomere mediated truncation of native chromosomes. These minichromosomes are faithfully transmitted from one generation to the next and provide an ideal platform for breeding genes into desired plant varieties with out problems, such as linkage drag, associated with standard breeding methods.
    Type: Grant
    Filed: May 9, 2007
    Date of Patent: August 9, 2011
    Assignee: The Curators of the University of Missouri
    Inventors: Weichang Yu, Juan M. Vega, James Birchler
  • Patent number: 7989202
    Abstract: The present invention provides for the nucleic acid sequences of plant centromeres. This will permit construction of stably inherited recombinant DNA constructs and minichromosomes which can serve as vectors for the construction of transgenic plant and animal cells.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: August 2, 2011
    Assignees: The University of Chicago, Chromatin, Inc.
    Inventors: Jennifer M. Mach, Helge Zieler, RongGuan Jin, Kevin Keith, Gregory P. Copenhaver, Daphne Preuss
  • Patent number: 7989395
    Abstract: The present invention provides a method for identifying a compound of interest by screening libraries of molecules which include an encoding oligonucleotide tag.
    Type: Grant
    Filed: October 23, 2006
    Date of Patent: August 2, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Barry Morgan, Stephen Hale, Christopher C. Arico-Muendel, Matthew Clark, Richard Wagner, David I. Israel, Malcolm L. Gefter, Dennis Benjamin, Nils Jakob Vest Hansen, Malcolm J. Kavarana, Steffen Phillip Creaser, George J. Franklin, Paolo A. Centrella, Raksha A. Acharya
  • Patent number: 7947443
    Abstract: The electrical conductivity of DNA and other oligonucleotide constructs is dependent on its conformational state. Such a dependence may be harnessed for the electronic sensing of external analytes, for instance, adenosine or thrombin. Such a DNA sensor incorporates an analyte receptor, whose altered conformation in the presence of bound analyte switches the conformation, and hence, the conductive path between two oligonucleotide stems, such as double-helical DNA. Two distinct designs for such sensors are described that permit significant electrical conduction through a first or “detector” double-helical stem only in the presence of the bound analyte. In the first design, current flows through the analyte receptor itself whereas, in the second, current flows in a path adjacent to the receptor.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: May 24, 2011
    Assignee: Simon Fraser University
    Inventors: Dipankar Sen, Richard P. Fahlman, Hua Zhong Yu, Bixia Ge, Yu Chuan Huang
  • Patent number: 7943301
    Abstract: The electrical conductivity of DNA and other oligonucleotide constructs is dependent on its conformational state. Such a dependence may be harnessed for the electronic sensing of external analytes, for instance, adenosine. Such a DNA sensor incorporates an analyte receptor, whose altered conformation in the presence of bound analyte switches the conformation, and hence, the conductive path between two oligonucleotide stems, such as double-helical DNA. Two distinct designs for such sensors are described that permit significant electrical conduction through a first or “detector” double-helical stem only in the presence of the bound analyte. In the first design, current flows through the analyte receptor itself whereas, in the second, current flows in a path adjacent to the receptor.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: May 17, 2011
    Assignee: Simon Fraser University
    Inventors: Dipankar Sen, Richard P. Fahlman
  • Patent number: 7935658
    Abstract: The present invention provides methods of synthesizing libraries of molecules comprising a functional moiety which is operatively linked to an encoding oligonucleotide.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: May 3, 2011
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Barry Morgan, Stephen Hale, Christopher C. Arico-Muendel, Matthew Clark, Richard Wagner, David I. Israel, Malcolm L. Gefter, Dennis Benjamin, Nils Jakob Vest Hansen, Malcolm J. Kavarana, Steffen Phillip Creaser, George J. Franklin, Paolo A. Centrella, Raksha A. Acharya
  • Patent number: 7932028
    Abstract: A probe and a primer capable of collectively detecting microorganisms of the same species while differentiating microorganisms of other species with an object of classification by species of fungus. An oligonucleotide probe for detecting an infectious etiologic microorganism gene includes at least one base sequence selected from the base sequences belonging to one group of the following first to ninth groups. The base sequence groups of first to ninth groups are: first group (SEQ ID NOS:1 to 5); second group (SEQ ID NOS:6 to 10); third group (SEQ ID NOS:11 to 15); fourth group (SEQ ID NOS:16 to 21); fifth group (SEQ ID NOS:22 to 26); sixth group (SEQ ID NOS:27 to 31); seventh group (SEQ ID NOS:32 to 36); eighth group (SEQ ID NOS:37 to 41); and ninth group (SEQ ID NOS:42 to 46).
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: April 26, 2011
    Assignee: Canon Kabushiki Kaisha
    Inventors: Toshifumi Fukui, Nobuhiro Tomatsu
  • Patent number: 7915037
    Abstract: The invention provides a Dre/rox recombinase system. In particular, the invention provides Dre polypeptides that can catalyze site-specific recombination at rox sites but not at lox sites. The Dre/rox system can be utilized in a number of genetic manipulations either alone or in combination with other recombinase systems.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: March 29, 2011
    Assignee: Stowers Institute for Medical Research
    Inventors: Brian L. Sauer, Jeffrey McDermott
  • Patent number: 7910328
    Abstract: Novel calcium-independent phospholipases A2; genes encoding the same; an antibody against them; an inherent promoter or a regulator gene which comprises a base sequence occurring in intron and inducing site-specific expression in response to an external stimulus; a method of expressing a target protein in response to an external stimulus; and an organism having this gene transferred thereinto. Novel calcium-independent phospholipases A2 having an amino acid sequence represented by SEQ ID NO: 1, 3 or 5 or an amino acid sequence derived from such an amino acid sequence by the substitution, deletion or addition of one or more amino acids; a gene having a base sequence occurring in an intron and being capable of initiating RNA transcription due to an external stimulus such as a stimulus with kainic acid or an electrical stimulus; a method of regulating expression by using the gene; and an organism having the gene transferred thereinto.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: March 22, 2011
    Assignee: Japan Science and Technology Agency
    Inventors: Takao Shimizu, Koji Kishimoto, Yasuyoshi Watanabe
  • Publication number: 20110041222
    Abstract: A nucleotide leader sequence 5?-UTR comprises elements favorable to gene expression, such as repeated CAA trinucleotide elements in combination with repeated CT dinucleotide elements.
    Type: Application
    Filed: December 27, 2007
    Publication date: February 17, 2011
    Applicant: UNIVERSITA 'DEGLI STUDI DI UDINE
    Inventors: Stefano Marchetti, Francesca De Amicis, Tamara Patti
  • Patent number: 7888123
    Abstract: An object of the present invention is to provide a transformation system for Labyrinthulomycota that allows the elucidation of biosynthetic mechanisms of lipids such as PUFA and carotenoids as well as for the construction of a high production system and the design and development of novel functional lipid molecules by the control of the mechanisms. The present invention provides a method for introducing a transgene into a cell of Labyrinthulomycota, which comprises introducing into a cell of Labyrinthulomycota a recombinant vector comprising a transgene and a nucleotide sequence which is homologous to a part of chromosomal DNA of Labyrinthulomycota and is capable of homologous recombination with the chromosomal DNA, and then inducing homologous recombination in this homologous nucleotide sequence.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: February 15, 2011
    Assignee: Fujifilm Corporation
    Inventors: Kazuhisa Ono, Tsunehiro Aki, Seiji Kawamoto
  • Publication number: 20100330667
    Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).
    Type: Application
    Filed: June 4, 2010
    Publication date: December 30, 2010
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Valérie BAUBET, Hervé Le Mouellic, Philippe Brulet
  • Patent number: 7846687
    Abstract: Cytomegalovirus (CMV) Intron A fragments for expressing gene products are disclosed. Also described are expression vectors including the fragments, as well as methods of using the same.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: December 7, 2010
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Kent B. Thudium, Mark Selby
  • Patent number: 7803365
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel in vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a method to deliver a gutless adenovirus vector carrying a DNA sequence encoding a TM protein or its variant using a stent.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: September 28, 2010
    Assignee: Biovec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Publication number: 20100222238
    Abstract: A pair of asymmetrical, partially double-stranded oligonucleotide adapters are provided wherein the pair of adapters comprise a first asymmetrical oligonucleotide adapter comprising a single-stranded 3? overhang and a second asymmetrical double-stranded oligonucleotide adapter comprising a single-stranded 5? overhang and at least one blocking group on the strand of said second asymmetrical oligonucleotide adapter that does not comprise the 5? overhang. Also provided are a pair of double-stranded Y oligonucleotide adapters and a pair of double-stranded bubble oligonucleotide adapters and methods of using said asymmetrical adapters for amplification of at least one double stranded nucleic acid molecule, wherein the amplification produces a plurality of amplified nucleic acid molecules having a different nucleic acid sequence at each end are also described. Also provided is a method for exponentially amplifying one strand in a double-stranded nucleic acid molecule.
    Type: Application
    Filed: November 30, 2009
    Publication date: September 2, 2010
    Applicant: LIFE TECHNOLOGIES CORPORATION
    Inventors: Douglas R. Smith, Joel A. Malek
  • Patent number: 7785843
    Abstract: Provided herein are libraries of nucleic acid species each comprising a transcription unit having a promoter region operatively linked to a coding sequence. The coding sequence of each nucleic acid species encodes a RNA cleavage substrate comprising a unique compomer species and a cleavage site. Each compomer species has a molecular mass distinguishable from the molecular mass of other compomer species in the library, and cleavage at a cleavage site releases a polynucleotide comprising the compomer species from the RNA cleavage substrate.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: August 31, 2010
    Assignee: Sequenom, Inc.
    Inventors: Mathias Ehrich, Dirk Johannes Van den Boom
  • Patent number: 7786279
    Abstract: Polynucleotides and polypeptides which participate in influenza virus infection of cells and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and antibodies directed thereagainst for diagnosing, treating and preventing influenza virus infection.
    Type: Grant
    Filed: February 24, 2004
    Date of Patent: August 31, 2010
    Assignee: Yeda Research And Development Co. Ltd.
    Inventors: Ruth Arnon, Sung-Ho Jeon, Basak Kayhan, Tamar Ben-Yedidia
  • Patent number: 7767449
    Abstract: Disclosed is a method for producing a protein involving infecting a culture of eukaryotic cells with a recombinant vaccinia virus.
    Type: Grant
    Filed: April 18, 1994
    Date of Patent: August 3, 2010
    Assignee: Health Research Incorporated
    Inventor: Enzo Paoletti
  • Publication number: 20100184022
    Abstract: A probe suitable for coupling with a particulate support such as a microbead, the probe comprising: a) a coupling group which permits coupling of the probe to the surface of the particulate support; b) a spacer; and c) a target-specific oligonucleotide probe sequence, wherein the spacer comprises: i) an oligonucleotide spacer of at least 15 nucleotides between the target specific probe sequence and the support coupling group; and optionally ii) a carbon spacer of between 3 and 50 carbon units between the target specific probe sequence and the support coupling group.
    Type: Application
    Filed: January 16, 2007
    Publication date: July 22, 2010
    Inventor: Brigitte Desiree Alberte Colau
  • Patent number: 7759097
    Abstract: An object of the present invention is to provide a transformation system for Labyrinthulomycota that allows the elucidation of biosynthetic mechanisms of lipids such as PUFA and carotenoids as well as for the construction of a high production system and the design and development of novel functional lipid molecules by the control of the mechanisms. The present invention provides a vector for the transformation of Labyrinthulomycota with a transgene, which comprises at least (1) a nucleotide sequence which is homologous to a part of chromosomal DNA of Labyrinthulomycota and is capable of homologous recombination with the chromosomal DNA, (2) a selection marker gene having a promoter sequence located upstream and a terminator sequence located downstream, and (3) a cloning site for transgene insertion having a promoter sequence located upstream and a terminator sequence located downstream.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: July 20, 2010
    Assignees: Fujifilm Corporation, Hiroshima University
    Inventors: Kazuhisa Ono, Tsunehiro Aki, Seiji Kawamoto
  • Patent number: 7754944
    Abstract: Synthetic modular polynucleotide constructs are useful for gene expression in plants, methods for making and using such constructs, and plants transformed with such constructs. The constructs comprise unique restriction sites for each modular element and may further comprise polynucleotide identifier sequences.
    Type: Grant
    Filed: April 2, 2007
    Date of Patent: July 13, 2010
    Assignee: Monsanto Technology LLC
    Inventors: Changlin Fu, Brian Hauge, Vicky Gavrias
  • Patent number: 7749701
    Abstract: A method for controlling the use of oligonucleotide sequences released from arrays, comprises synthesizing a chemical array of oligonucleotides on a substrate under conditions for producing an array of cleavable oligonucleotides that are blocked from enzymatic reactions after cleavage. Methods may also include receiving a chemical array of cleavable oligonucleotides on a substrate, and cleaving the oligonucleotides from the array, wherein the oligonucleotides are blocked from enzymatic reactions after cleavage. Arrays, populations of oligonucleotides and kits are also provided to facilitate the methods.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: July 6, 2010
    Assignee: Agilent Technologies, Inc.
    Inventors: Eric M Leproust, Michael G. Booth
  • Patent number: 7749751
    Abstract: The present invention relates to T-DNA vectors and methods for obtaining transgenic eukaryotes using said vectors. The transgenic eukaryotes are characterized in that they contain the T-DNA but not the illegitimately transferred vector backbone sequence. This is achieved by modifying the T-DNA borders such that they are more efficiently nicked or such that they allow elimination of illegitimately transferred vector backbone sequences by means of recombination.
    Type: Grant
    Filed: December 13, 2000
    Date of Patent: July 6, 2010
    Assignee: CropDesign N.V.
    Inventors: Anna Depicker, Vladimir Mironov, Franky Terras, Willem Broekaert, Sylvie De Buck, Chris De Wilde
  • Publication number: 20100167952
    Abstract: The present invention provides for compositions, methods and systems for targeted sequence enrichment. In particular, the present invention provides for enriching for targeted nucleic acid sequences during hybridizations in microarray assays by suppressing secondary capture of non-target nucleic acid sequences.
    Type: Application
    Filed: September 3, 2009
    Publication date: July 1, 2010
    Inventors: Thomas Albert, Jeff Jeddeloh, Bradley Swanson
  • Patent number: 7745594
    Abstract: This invention relates to nucleic acid-based logic gates. The invention further relates to circuits comprising nucleic acid-based logic gates and methods of performing operations with the gates and circuits provided herein.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: June 29, 2010
    Assignee: California Institute of Technology
    Inventors: Georg Seelig, David Soloveichik, Erik Winfree, David Zhang
  • Patent number: 7745592
    Abstract: The invention relates to a new “gene-switch” (cumate-inducible switch) for mammalian cells. This switch is as useful in the development of expression systems and cell-based assays for functional genomics as in the generation of viral vectors for gene therapy.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: June 29, 2010
    Assignee: National Research Council of Canada
    Inventors: Bernard Massie, Alaka Mullick, Peter C. K. Lau, Yasuo Konishi
  • Patent number: 7745606
    Abstract: The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: June 29, 2010
    Assignee: Dynavax Technologies Corporation
    Inventors: Dino Dina, Karen L. Fearon, Jason Marshall
  • Patent number: 7741042
    Abstract: The present invention relates to a method for producing a DNA chip, which comprises the steps of: (a) cloning a probe, where a linker is coupled to one or both ends of an oligonucleotide to be integrated on a slide, into a vector; (b) transforming host cells with the vector; (c) culturing the transformed host cells, to recover the probe where the linker is coupled to one or both ends of the oligonucleotides; and (d) integrating the recovered double-helical probes on a slide. Also, the present invention relates to a DNA chip for HPV diagnosis produced by the method, and a method for diagnosing the presence or genotype of HPV using the DNA chip.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: June 22, 2010
    Assignee: Genomictree, Inc.
    Inventors: Sung-Whan An, Chi-Wang Yoon, Tae-Jeong Oh, Dae-Kyung Yoon, Sun-Woo Lee, Myung-Soon Kim, Suk-Kyung Woo, Keun Ha Kim
  • Patent number: 7736897
    Abstract: Methods and compositions using populations of randomized modified FRT recombination sites to identify, isolate and/or characterize modified FRT recombination sites are provided. The recombinogenic modified FRT recombination sites can be employed in a variety of methods for targeted recombination of polynucleotides of interest, including methods to recombine polynucleotides, assess promoter activity, directly select transformed organisms, minimize or eliminate expression resulting from random integration into the genome of an organism, such as a plant, remove polynucleotides of interest, combine multiple transfer cassettes, invert or excise a polynucleotide, and identify and/or characterize transcriptional regulating regions are also provided.
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: June 15, 2010
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Yumin Tao, Dennis L. Bidney, William J. Gordon-Kamm, Leszek A. Lyznik
  • Patent number: 7720614
    Abstract: A computational method is described which uses the process of cis-regulatory module evolution to identify conserved sequence patches which exhibit suppression of change by snp/indel occurrence, including determining sequence similarities significantly greater than random expectation on selected genome sequences from two or more species in sequences that lie outside of protein coding regions, sorting the similarities for conserved patches of single nucleotide polymorphisms (SNPs) and insertion/deletions (indels). and selecting such patches to identify cis-regulatory modules. Further, the disclosed method is practiced in the absence of having to execute multiple interspecific sequence comparison analysis, where such identified cis-regulatory modules are used to produce libraries and arrays containing such cis-regulatory modules.
    Type: Grant
    Filed: December 7, 2005
    Date of Patent: May 18, 2010
    Assignee: California Institute of Technology
    Inventors: Eric H. Davidson, Robert Andrew Cameron
  • Patent number: 7718622
    Abstract: The present invention provides compositions comprising conjugate molecules that are structurally stable at a temperature of between about 2 degrees C. and 8 degrees C. In some examples, a conjugate molecule comprises an antigen, such as an allergen. In some examples, a conjugate molecule comprises the Ragweed antigen Amb a 1. The present invention provides methods for making and using such compositions. Provided herein are methods for modulating an immune response in an individual comprising administration of a composition comprising a structurally stable conjugate molecule as described herein.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: May 18, 2010
    Assignee: Dynavax Technologies Corporation
    Inventors: Stephen F. Tuck, Roberto Rodriguez
  • Patent number: 7718784
    Abstract: In one embodiment, the present invention relates to fluorescent nucleic acid constructs and methods of using these switchable constructs to rapidly screen for target molecule interactions. More particularly, an RNA/DNA chimera comprising a fluorophore-quencher pair and a nucleic acid construct is disclosed for the rapid screening of interactions between the HIV-1 nucleocapsid protein, NCp7, and a stem-loop region, SL3, of the HIV-1 RNA, or antagonists thereof. The compositions and methods disclosed herein can be used in preferred aspects of the present invention for diagnosing disease states, distinguishing the presence of infectious or toxic agents, drug discovery and design, and molecular electronic applications.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: May 18, 2010
    Assignee: Syracuse University
    Inventors: Philip N. Borer, Bruce S. Hudson, Christopher L. DeCiantis
  • Patent number: 7713522
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: May 11, 2010
    Assignee: BioVec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Patent number: 7700315
    Abstract: A novel gene of Bifidobacteria and the polypeptides encoded thereby. In particular, a gene belonging to the Serpin superfamily and its use in the production of bacterial Serpins is provided. Also provided are vectors, host cells, and methods for producing bacterial Serpin polynucleotides and/or polypeptides.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: April 20, 2010
    Assignee: Nestec S.A.
    Inventors: Fabrizio Arigoni, Stéphanie Blum, Michèle Delley, Mark Alan Schell, Eduardo Schiffrin
  • Patent number: 7700570
    Abstract: The invention provides new methods for modulating specific CMI-inducing cytokines in vivo. Such new methods result in stimulation of the cytokines IL-6, IL-12 MIP-1? and MCP without substantially inducing undesired cytokines. The methods according to the invention are based upon administration of oligonucleotides containing particular structural motifs which lead to specific cytokine induction.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: April 20, 2010
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Sudhir Agrawal, Qiuyan Zhao
  • Patent number: 7696335
    Abstract: The invention provides methods, kits, and compositions comprising novel mutant loxP sites. Such sites are particularly useful for procedures requiring multiple site-specific recombination reactions, including deletions or insertions of multiple genes or other sequences in the same organism, staged insertions or deletions of genes of the same organism at different times, assembly of large polynucleotide constructs by serial site-specific recombination, and the like. In one aspect, compositions of the invention includes particular mutant spacer oligonucleotides of loxP recombination elements, the recombination elements themselves, and pairs of non-promiscuous mutant loxP sites.
    Type: Grant
    Filed: October 12, 2006
    Date of Patent: April 13, 2010
    Assignee: BC Cancer Agency
    Inventors: Robert A. Holt, Perseus I. Missirlis
  • Patent number: 7687058
    Abstract: The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or its variant into a segment of a blood vessel ex vivo using a gutless adenovirus vector. Another aspect of the present invention is to provide a gutless adenovirus vector carrying a transgene, such as a gene encoding TM protein or its variant.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: March 30, 2010
    Assignee: BioVec, LLC
    Inventors: Lakshman R. Sehgal, Jonathan Wong
  • Patent number: 7674777
    Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: March 9, 2010
    Assignees: University of Iowa Research Foundation, The United States of America as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.
    Inventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
  • Patent number: 7674892
    Abstract: The hsp70 gene from an Arthrobacter species has been isolated and sequenced. The encoded protein is believed to be highly immunogenic, especially in fish, and also has utility as a non-specific adjuvant, and as an adjuvanting carrier for heterologous antigens.
    Type: Grant
    Filed: July 14, 2003
    Date of Patent: March 9, 2010
    Assignee: Novartis AG
    Inventors: Steven Gareth Griffiths, Rachael Jane Ritchie, Nathalie C. Simard
  • Patent number: 7670823
    Abstract: The present invention relates generally to compositions and methods for use in recombinational cloning of nucleic acid molecules. In particular, the invention relates to nucleic acid molecules encoding one or more recombination sites or portions thereof, to nucleic acid molecules comprising one or more of these recombination site nucleotide sequences and optionally comprising one or more additional physical or functional nucleotide sequences. The invention also relates to vectors comprising the nucleic acid molecules of the invention, to host cells comprising the vectors or nucleic acid molecules of the invention, to methods of producing polypeptides using the nucleic acid molecules of the invention, and to polypeptides encoded by these nucleic acid molecules or produced by the methods of the invention. The invention also relates to antibodies that bind to one or more polypeptides of the invention or epitopes thereof.
    Type: Grant
    Filed: March 2, 2000
    Date of Patent: March 2, 2010
    Assignee: Life Technologies Corp.
    Inventors: James L. Hartley, Michael A. Brasch, Gary F. Temple, David Cheo
  • Patent number: 7662949
    Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: February 16, 2010
    Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.
    Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
  • Patent number: 7662623
    Abstract: Vector constructs for expression of two or more functional proteins or polypeptides under operative control of a single promoter and methods of making and using the same are described. The vectors comprise a self-processing cleavage site between each respective protein or polypeptide coding sequence. The vector constructs include the coding sequence for a self-processing cleavage site and may further include an additional proteolytic cleavage sequence which provides a means to remove the self processing peptide sequence from expressed protein(s) or polypeptide(s). The vector constructs find utility in methods for enhanced production of biologically active proteins and polypeptides in vitro and in vivo.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: February 16, 2010
    Assignee: BioSante Pharmaceuticals, Inc.
    Inventors: Jianmin Fang, Karin Jooss, Andrew Simmons, Jing-Jing Qian
  • Patent number: 7662621
    Abstract: This invention pertains to BIV constructs encompassing BIV combination vectors, BIV vectors and BIV packaging vectors and particularly the invention pertains to a three vector system comprising: a) a BIV vector construct including a DNA segment from a BIV genome, a packaging sequence to package RNA into virions; a promoter operably linked to the DNA segment; and a transgene operably linked to a second promoter; b) a BIV packaging vector construct comprising a BIV DNA sequence fragment comprising at least a gag gene or pol gene of BIV; a promoter operably linked to the BIV DNA fragment; and a polyadenylation sequence located downstream of the BIV DNA fragment; and c) an expression vector construct comprising a gene encoding a viral surface protein. Also provided is a method for transferring a gene of interest into a mammalian cell.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: February 16, 2010
    Assignee: Novartis AG
    Inventors: Tianci Luo, Robert David Berkowitz, Michael Kaleko
  • Patent number: 7645868
    Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described.
    Type: Grant
    Filed: January 25, 2002
    Date of Patent: January 12, 2010
    Assignee: Luminex Molecular Diagnostics, Inc.
    Inventors: Daniel Kobler, Daniel Fieldhouse